⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614993 | 0.94 | — | — | |
| SCHEMBL28907895 | 0.79 | HRH3 (0.46) | — | |
| SCHEMBL66077 | 0.72 | — | — | |
| SCHEMBL3770379 | 0.72 | — | — | |
| SCHEMBL678884 | 0.72 | — | — | |
| SCHEMBL25433068 | 0.72 | POLB (0.48) | — | |
| SCHEMBL7286457 | 0.72 | HRH3 (0.50) | — | |
| SCHEMBL967274 | 0.72 | — | — | |
| SCHEMBL238611 | 0.71 | HRH3 (0.62) | — | |
| SCHEMBL15650449 | 0.70 | POLB (0.81) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233770-B1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1351722-B1 | ENDOSSEOUS IMPLANT | UNIV GENEVE (CH) | 2006-07-05 | — | — | EP | claimed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | claimed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | claimed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | claimed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | claimed |
| JP-2002539192-A | — | — | 2002-11-19 | — | — | JP | claimed |
| WO-2002080920-A1 | ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2002070519-A1 | MONOBACTAMS AS CATHEPSIN K INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | claimed |
| WO-2002040073-A1 | ENDOSSEOUS IMPLANT | UNIVERSITÉ DE GENÈVE (CH) | 2002-05-23 | — | — | WO | claimed |
| EP-1171097-A1 | A PHARMACEUTICAL FORMULATION COMPRISING AN BISPHOSPHONATE AND AN ADDITIVE AGENT PROVIDING AN ENHANCED ABSORPTION OF THE BISPHOSPHONATE | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | claimed |
| EP-1161415-A2 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2001068645-A2 | N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2000061111-A1 | A PHARMACEUTICAL FORMULATION COMPRISING AN BISPHOSPHONATE AND AN ADDITIVE AGENT PROVIDING AN ENHANCED ABSORPTION OF THE BISPHOSPHONATE | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | claimed |
| WO-2000055126-A2 | N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-1021194-A1 | NEW IMPROVED FORMULATION FOR TREATMENT OF OSTEOPOROSIS | AstraZeneca AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018972-A1 | NEW IMPROVED FORMULATION FOR TREATMENT OF OSTEOPOROSIS | ASTRAZENECA AB (SE) | 1999-04-22 | — | — | WO | claimed |
| EP-3150235-B1 | BONE FILLER COMPOSITION | DEPUY INT LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| EP-0806954-A1 | INHIBITION OF THE DEGRADATION OF CONNECTIVE TISSUE MATRIX PROTEIN COMPONENTS IN MAMMALS | Teronen, Olli Pekka (FI) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023505-A1 | INHIBITION OF THE DEGRADATION OF CONNECTIVE TISSUE MATRIX PROTEIN COMPONENTS IN MAMMALS | TERONEN OLLI PEKKA (FI) | 1996-08-08 | — | — | WO | disclosed |